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Abstract
Background: The difference in epilepsy burden existing among populations in tropical regions has been attributed to many
factors, including the distribution of infectious diseases with neurologic sequels. To define the burden of epilepsy in Latin
American Countries (LAC) and to investigate the strength of association with neurocysticercosis (NCC), considered one of
the leading causes of epilepsy, we performed a systematic review and meta-analysis of the literature.
Methodology: Studies published until 2012 were selected applying predefined inclusion criteria. Lifetime epilepsy (LTE)
prevalence, active epilepsy (AE) prevalence, incidence, mortality, treatment gap (TG) and NCC proportion among people
with epilepsy (PWE) were extracted. Median values were obtained for each estimate using random effects meta-analysis.
The impact of NCC prevalence on epilepsy estimates was determined using meta-regression models. To assess the
association between NCC and epilepsy, a further meta-analysis was performed on case-control studies.
Principal findings: The median LTE prevalence was 15.8/1,000 (95% CI 13.5–18.3), the median AE prevalence was 10.7/1,000
(95% CI 8.4–13.2), the median incidence was 138.2/100,000 (95% CI 83.6–206.4), the overall standardized mortality ratio was
1.4 (95% CI 0.01–6.1) and the overall estimated TG was 60.6% (95% CI 45.3–74.9). The median NCC proportion among PWE
was 32.3% (95% CI 26.0–39.0). Higher TG and NCC estimates were associated with higher epilepsy prevalence. The
association between NCC and epilepsy was significant (p,0.001) with a common odds ratio of 2.8 (95% CI 1.9–4.0).
Significance: A high burden of epilepsy and of NCC in LAC and a consistent association between these two diseases were
pointed out. Furthermore, NCC prevalence and TG were identified as important factors influencing epilepsy prevalence to
be considered in prevention and intervention strategies.
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Introduction
Epilepsy is one of the most prevalent non-communicable
neurologic diseases [1], with an estimated aggregate burden of
around 0.5% of the total disease burden [2]. It affects approxi-
mately 70 million people worldwide [3] and at least five million
people in Latin American Countries (LAC) [4].
The epidemiological studies describing the burden of epilepsy
across the world have frequently reported the presence of
important differences in the estimate of prevalence and incidence
[5]. The median lifetime epilepsy (LTE) prevalence, ranges from
5.8/1,000 (range 2.7–12.4) in developed countries to 15.4/1,000
(range 4.8–49.6) in rural areas of developing countries [3], and
similar variations are also reported for active epilepsy (AE)
prevalence and for incidence [6]. Considering LAC, the median
LTE prevalence ranges from 6/1,000 to 43.2/1,000, while the
median AE prevalence from 5.1/1,000 to 57/1,000 [7], showing a
very large range of variability.
The wide prevalence difference existing among populations
may be mainly attributed to country resources and development-
related factors [8] to spatial clustering of etiologic and risk factors
[9], and to methodological limitations of studies [10]. In a recent
review on the global burden of epilepsy, a meta-regression analysis
showed that location, study size and age of study participants explained
53% of the variance in LTE prevalence [3].
However among the factors probably responsible of the
unexplained amount of variance, the distribution of epilepsy-
related biological and environmental factors, such as infections of
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the central nervous system (CNS), may be important, especially in
resource limited countries, but had never been taken into
consideration in previous meta-analysis.
Among CNS infections, neurocysticercosis (NCC) is considered
the leading cause of acquired epilepsy in the developing world
[11,12]. Although it has been declared eradicable by the
International Task Force for Disease Eradication of World Health
Organization (WHO) in 1993, NCC is still recognized as a ‘‘major
neglected disease’’ due to the lack of information about its burden
and transmission, the lack of diagnostic tools available in resource-
poor areas, and the lack of intervention strategies for its control
[13]. Recent data indicate that NCC represents a significant
health problem in endemic areas, causing epilepsy in 0.6–1.8% of
the population [13]. This indicates that between 450,000 and 1.35
million persons suffer from epilepsy due to NCC in LAC only [14].
Understanding the reasons that influence epilepsy distribution is
crucial to improve and tailor intervention programs and preven-
tion strategies. Thus, to better define the burden of epilepsy of
NCC and their association in LAC, we conducted a systematic
review and meta-analysis of epilepsy prevalence, incidence,
mortality, treatment gap (TG) and of NCC prevalence among
people with epilepsy (PWE) in LAC.
Methods
Search strategy
Two systematic searches, without language restriction, were
conducted to identify all relevant articles concerning ‘‘burden of
epilepsy’’ and ‘‘prevalence and association between cysticercosis
(CC)/NCC and epilepsy’’. The following electronic databases
were independently examined by two authors (EB and JB) to
identify articles published until the 1st July, 2012: MEDLINE,
IMBIOMED, LILACS, EMBASE, SciELO, PAHO Library
Online Catalog, PAHO Evidence Portal, WHOLIS, Cochrane
Library. Additional searches were performed on bibliographies of
pertinent original articles, reviews, abstracts and book chapters.
Combined text words and Medical Subject Headings (MeSH)
terminology were used. Searches were organized using the
following search terms to develop a search strategy: ‘‘epilep*’’
and ‘‘mortality’’, ‘‘ preval*’’, ‘‘incidenc*’’, ‘‘epidemiol*’’, ‘‘
surve*’’, ‘‘rate*’’, ‘‘frequenc*’’, ‘‘treatment gap’’, ‘‘cysticerc*’’,
‘‘neurocysticerc*’’, ‘‘taenia*’’, ‘‘Argentina’’, ‘‘Bolivia’’, ‘‘Brazil’’,
‘‘Chile’’, ‘‘Colombia’’, ‘‘Costa Rica’’, ‘‘Cuba’’, ‘‘Dominican
Republic’’, ‘‘Ecuador’’, ‘‘El Salvador’’, ‘‘Guatemala’’, ‘‘Guyana’’,
‘‘Honduras’’, ‘‘Mexico’’, ‘‘Nicaragua’’, ‘‘Panama’’, ‘‘Paraguay’’,
‘‘Peru’’, ‘‘Puerto Rico’’, ‘‘Suriname’’, ‘‘Uruguay’’, ‘‘Venezuela’’,
‘‘Latin America’’. The literature search was adapted for the
different databases.
Selection criteria
Burden of epilepsy. We included retrospective cross-sec-
tional or prospective studies measuring prevalence, incidence,
mortality or TG of epilepsy in adults or children from LAC.
A paper was included if it reported a definition of epilepsy as
two or more unprovoked seizures occurring at least 24 hours apart
[15], if it included an accepted definition of LTE and AE [15], and
provided the denominator of the population. We also included
studies published before 1993 if a definition of epilepsy,
comparable with those above-mentioned, was provided. Regard-
ing TG, the studies meeting the definition proposed by the
International League Against Epilepsy [16], were included. Data
should have been collected through standardized questionnaires in
door-to-door survey. A study was excluded if it explored only acute
symptomatic seizures or specific seizure patterns or epileptic
syndromes. Data from reviews, editorials, abstracts, letters to the
editor and studies of subpopulation were excluded.
NCC prevalence among PWE. Retrospective cross-sectional
or prospective studies measuring the prevalence of NCC among
PWE in LAC were included if they reported a definition of
epilepsy, the description of ascertainment methods of epilepsy,
NCC diagnostic methods (reported below), and study population:
rural/urban, community/hospital (inpatient/outpatient).
The diagnosis of NCC is currently based on a set of criteria
including clinical evaluation, radiological, immunological and
epidemiological data, that results in two categories of diagnostic
certainty: definite and probable NCC [17]. We included studies in
which the diagnosis of NCC met the definition of probable or
definite according to the above mentioned criteria [17]. Therefore,
we included studies combining neuroimaging, both brain
computed tomography (CT) scan or magnetic resonance imaging
(MRI), to serum enzyme-linked immunoelectrotransfer blot
(EITB) assay, whose specificity approaches 100% and sensitivity
94–98% for patients with two or more cystic or enhancing lesions
[18]. Studies detecting anticysticercal antibodies by cerebrospinal
fluid (CSF) enzyme-linked immunosorbent assay (CSF AbELISA)
were also included [19]. Studies using only serum antibody
enzyme-linked immunosorbent assay (AbELISA) or serum antigen
enzyme-linked immunosorbent assay (AgELISA) were not includ-
ed [20].
Association between CC/NCC and epilepsy. Studies
meeting the following criteria were included in the meta-analysis:
presence of a control group (people without epilepsy, PWOE);
information about methods and criteria used for case-finding and
control selection; possibility to determine the sample size of each of
the following four groups: PWE affected by CC (PWE CC+), PWE
not affected by CC (PWE CC2), PWOE affected by CC (PWOE
CC+), PWOE not affected by CC (PWOE CC2), presence of a
valid diagnostic method to assess CC/NCC (either brain CT,
brain MRI, serum EITB, or CSF AbELISA). Serum AbELISA
and serum AgELISA were not considered valid diagnostic
Author Summary
Epilepsy affects approximately 70 million people world-
wide and at least five million people in Latin America.
Many researchers have pointed out a different distribution
of epilepsy in Latin American countries, with some regions
presenting higher frequencies and others presenting lower
frequencies. This difference in epilepsy distribution has
been attributed to many factors, mainly related to the
allocation of health resources and to the presence of
environmental and infectious risk factors. Among the latter
stands neurocysticercosis, a parasitic disease that has been
recognized as the leading cause of acquired epilepsy in the
developing world, with a particularly elevated distribution
in rural settings. In this study, we performed a statistical
analysis to investigate whether neurocysticercosis distri-
bution affects epilepsy distribution among Latin American
countries and the relationship between these two condi-
tions. The combined results of the studies included
indicated that neurocysticercosis influences epilepsy fre-
quency in Latin America, as countries with higher epilepsy
distribution presented also higher neurocysticercosis fre-
quency. Moreover, another analysis pointed out an
association between the two diseases. These results
appear very important considering that parasitic infections
are modifiable factors and that their reduction may
contribute to decrease epilepsy burden worldwide.
Epilepsy and Neurocysticercosis in Latin America
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methods for the frequently reported false positive results with the
first and false negative results with the second technique [21].
Data extraction
Two reviewers (EB and JB) independently assessed the titles and
abstracts of all the studies identified. The full copies of papers
requiring further consideration were obtained. Relevant studies
were selected according to the criteria outlined above and data
were independently extracted on a predefined collecting form.
Statistical analysis
Burden of epilepsy and of NCC among PWE. Crude
prevalence was expressed as the number of cases per 1,000 people.
We recalculated the 95% confidence intervals (95% CI) around the
estimates provided. Crude incidence estimates were expressed per
100,000 persons per years +/295% CI. Mortality estimates were
reported using standardized mortality ratios (SMR) +/295% CI.
Magnitude of the TG was expressed as a percentage +/295% CI.
To estimate pooled median epilepsy prevalence, incidence,
mortality and TG we separately fitted random effects models to
log-transformed observed estimates using STATA v12 (Stata
Corp., TX). LTE and AE were analyzed separately. Similarly, the
pooled median NCC prevalence among PWE was obtained. For
all meta-analysis we obtained estimates of the median, 95% CI of
distribution of true prevalence and incidence by back-transforming
the logit scale to the original estimates. The analysis was separately
applied to the studies stratified by setting (urban/rural), by age
groups (adults/children) and, for NCC prevalence, by diagnostic
method (neuroimaging/EITB assay).
Forest plots were used to visualize the heterogeneity among the
studies [22]. We used the Cochrane chi-square (x2) test to examine
the null hypothesis that the observed heterogeneity was due to
sampling error [23] and calculated the degree of heterogeneity
using the statistic I2 [24]. A value .50% was considered as
substantial heterogeneity.
The influence of NCC prevalence on epilepsy prevalence (LTE
and AE), incidence and mortality was assessed using random
effects meta-regression. For each country and for each setting
(rural/urban), NCC proportion among PWE was considered as a
binary variable (low/high) dichotomized according to the median
Table 1. Median lifetime epilepsy prevalence, active epilepsy prevalence, incidence, mortality, treatment gap and
neurocysticercosis prevalence among people with epilepsy.
Estimate Covariate
Number of
studies Median estimate
95% Confidence
Intervals
LTE Rural 15 18.6/1,000 15.3–22.1
Urban 22 14.0/1,000 11.3–17.0
Total 36 15.8/1,000 13.5–18.3
Adults 2 33.0/1,000 26.4–41.8
Children 8 12.3/1,000 7.4–18.3
All age groups 25 15.7/1,000 13.4–18.1
AE Rural 12* 13.5/1,000 10.2–17.2
Urban 10* 7.8/1,000 4.9–11.4
Total 21 10.7/1,000 8.4–13.2
Adults 2 34.3/1,000 6.6–82.6
Children 2 3.6/1,000 1.4–6.9
All age groups 18 10.4/1,000 8.2–12.9
Incidence Rural 3* 138.4/100,000 50.6–269.3
Urban 3* 121.7/100,000 77.5–175.7
Total 5 138.2/100,000 83.6–206.4
Mortality (SMR) Rural 1 1.3 0.7–2.39
Urban 2 / /
Total 3 1.4 0.01–6.1
TG Rural 9* 77.8/100 67.4–86.8
Urban 6* 26.2/100 10.2–46.4
Total 14 60.6/100 45.3–74.9
NCC prevalence: EITB assay Rural 11 23.7/100 17.6–30.3
Urban 5 12.1/100 9.3–15.3
Total 16 19.6/100 14.8–24.9
NCC prevalence: CT scan Rural 9 37.5/100 26.3–49.4
Urban 11 29.4/100 21.4–37.4
Total 20 32.3/100 26.0–39.0
AE: active epilepsy; EITB: enzyme-linked immunoelectrotransfer blot; CT scan: computed tomography scan; LTE: lifetime epilepsy; NCC: neurocysticercosis;
SMR: standardized mortality ratio; TG: treatment gap.
*one study (Placencia et al., 1992) reported separated data for both urban and rural settings.
doi:10.1371/journal.pntd.0002480.t001
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value of the seroprevalence (EITB assay) estimated. We performed
both univariate and multivariable analysis adjusting the model for
variables that could influence epidemiological estimates: study
setting (urban, rural), age of study participants (all, adults,
children), method of data collection and ascertainment of epilepsy
cases (questionnaires and neurological examination, instrumental
ascertainment), type of estimate (point, period), study size
(.20,000; 1,000–20,000; ,1,000), definition of epilepsy (ILAE
1993, others), screening questionnaire (WHO, others), validation
of the questionnaires (validated, not validated) and level of TG
dichotomized (#50%, .50%). Study design (retrospective or
prospective) was also a variable evaluated for incidence estimate.
Using a backward stepwise procedure, we included in the
multivariable model all variables that showed evidence of an
association at the significance level p#0.25 in the univariate
analysis. At each step, nonsignificant explanatory variables were
removed and only variable with p#0.05 were retained in the
model.
Association between CC/NCC and epilepsy. To estimate
the association between CC/NCC and epilepsy in LAC we
performed a further meta-analysis of case-control studies, applying
a random effects model. Odds ratios (ORs) and 95% CI were
determined. To account for the different diagnostic methods, the
analysis was separately applied to the studies using EITB, and for
studies also using neuroimaging.
Results
Studies identified
Flowcharts of the literature searches are shown in figure S1 and
S2. Of 48 retained articles on epilepsy burden (table S1), 41
reported prevalence, five incidence, 14 TG and five mortality
(table S2). Most studies evaluated both adults and children and
methods of ascertainment of epilepsy were mainly based on both
questionnaire and neurological examination. The screening
instruments more frequently adopted were the 1991 WHO
questionnaire (WHO, 1991) and the questionnaires used by
Placencia [25–31] and by Pradilla [32,33]. The 1993 ILAE
definition of AE was the most frequently used but some studies
reported a narrower time frame, considering the previous 24
months [33,34] or the previous 12 months [35].
Thirty-one studies described the proportion of CC/NCC
among PWE in LAC (table S3 and S4). Proportion of patients
with positive brain CT scan ranged from 8.8% [36] to 70% [37].
Serological diagnosis of CC/NCC with EITB was performed in 16
studies, and the proportion ranged among 0% [38] and 39.5%
[30]. Thirteen studies associated to neuroimaging or EITB other
ascertainment methods for the diagnosis of CC/NCC, such as
serum AbELISA, serum AgELISA, CSF AbELISA, serum
ELISA/serum immunofluorescence assay, or CT/CSF test/
surgery [39], with proportions ranging from 0% [38] to 41.9%
[40].
The association between CC/NCC and epilepsy was evaluated
in ten of the 31 studies (table S4). In nine of them the association
was significant, with a OR ranging between 2.92 [41] and 12.25
[42]. Only one study reported absence of CC/NCC cases among
both PWE and controls [43].
Meta-analysis
Prevalence of epilepsy (LTE and AE) and of NCC among
PWE. The estimated median LTE prevalence for all studies
combined was 15.8/1,000 (95% CI 13.5–18.3) while median AE
prevalence was 10.7/1,000 (95% CI 8.4–13.2) (table 1). In rural
areas, LTE prevalence was 18.6/1,000 (95% CI 15.3–22.1) and
AE was 13.5/1,000 (95% CI 10.2–17.2), while in urban areas LTE
was 14.0/1,000 (95% CI 11.3–17.0) and AE was 7.8/1,000 (95%
CI 4.9–11.4). Results of the meta-analysis set by country are
illustrated in figure 1. Honduras presented the highest LTE
prevalence (23.3/1,000; 95% CI 19.8–27.3) while Argentina the
lowest (4.6/1,000; 95% CI 2.1–8.0). The marked variability
among studies was attributable to between-study heterogeneity for
both LTE (I2 = 95.9%; p,0.0001) and AE estimates (I2 = 90.4%;
Figure 1. Pooled life-time (LTE), active epilepsy (AE) prevalence (/1,000), NCC prevalence (by CT scan) and 95% confidence intervals
in Latin American countries. *estimates obtained from only one study.
doi:10.1371/journal.pntd.0002480.g001
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p,0.0001) (figure 2). Moreover, significant heterogeneity was
evidenced when stratifying on study setting (rural and urban;
I2.90) and on age group (children and adults; I2.90).
The estimated median NCC proportion among PWE for all
LAC was 32.3% (95% CI 26.0–39.0) by CT scan and 19.6% (95%
CI 14.8–24.9) by EITB assay (table 1). In rural areas proportion
was higher: 37.5% (CT scan) and 23.7% (EITB assay) versus
29.4% (CT scan) and 12.1% (EITB assay) reported in urban areas.
Results of the meta-analysis set by country are illustrated in figure 1
and detailed in table 2.
Multivariable random effects meta-regression (table 3 and 4)
showed that higher TG and NCC proportions were significantly
associated with higher LTE (OR 3.4; 95% CI 1.6–5.2) and AE
(OR 2.7; 95% CI 2.3–5.6) prevalence estimates. Together with
study setting and study size, these variables accounted for 61.8% of
the observed LTE prevalence heterogeneity. Considering AE
prevalence, TG, NCC prevalence , study setting, epilepsy
ascertainment and epilepsy definition accounted for 85.4% of
the observed heterogeneity.
Incidence of epilepsy. The estimated median incidence of
epilepsy for all the studies combined was 138.2/100,000 persons/
year (95% CI 83.6–206.4). In rural settings (table 1), the median
incidence rate was 138.4/100,000 persons/year (95% CI 50.6–
269.3), higher than that observed in urban settings: 121.7/100,000
persons/year (95% CI 77.5–175.7). The variability among studies
was attributable to a between-study heterogeneity (I2 = 66.4%;
Figure 2. Forest plots for life-time epilepsy prevalence/1,000 (A) and active epilepsy prevalence/1,000 (B) and 95% CI. Pooled LTE
prevalence for all studies (N = 37) was 15.8/1,000 (95% CI 13.5–18.3). Pooled AE prevalence for all studies (N = 21) was 10.7/1,000 (95% CI 8.4–13.2).
doi:10.1371/journal.pntd.0002480.g002
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p,0.02). Both the univariate and multivariable models found no
consistent associations between incidence estimates, NCC preva-
lence and TG (table S5).
Estimates of mortality and heterogeneity among
studies. The study conducted by da Mota Gomes et al. [44]
in Brazil was excluded from the meta-analysis because did not
provide the denominator (number of PWE), while the study
conducted by Devilat Barros et al. [45] was excluded because it
considered only children. The overall estimate of SMR (table 1) for
all the studies included was 1.4 (95% CI 0.01–6.1). The evaluation
of between-study heterogeneity was not significant (I2 = 0.0%;
p = 0.9).
Magnitude of the TG. The overall estimated TG was 60.6%
(95% CI 45.3–74.9), clearly different between rural (77.8%; 95%
CI 67.4–86.8) and urban (26.2%; 95% CI 10.2–46.4) settings
(table 1). There was a wide variability in the TG estimates among
studies, attributable to a between-study heterogeneity (I2 = 95.0%;
p,0.0001). Studies performed in rural settings were associated
with higher prevalence than those conduced in urban areas (OR
4.0; 95% CI 2.4–5.2). In the multivariable random effects meta-
regression model, study setting was significantly associated with
TG and accounted for about 60% of the observed heterogeneity
(table S6).
Association between CC/NCC and epilepsy. One study
[38], reporting absence of CC/NCC cases among both PWE and
PWOE, was excluded from the meta-analysis. A significant
(p,0.001) common OR of 2.8 (95% CI 1.9–4.0) was estimated
for all nine studies identified (figure 3). The test of heterogeneity
was not significant (p = 0.09), indicating homogeneity of the studies
included. The analysis with the eight studies using EITB
demonstrated a common OR of 2.7 (95% CI 1.9–3.7; p,0.001).
The test for heterogeneity was also not significant (p = 0.06). The
meta-analysis of the four studies using neuroimaging yielded an
OR of 5.6 (95% CI 2.7–11.3, p,0.001) with non-significant
heterogeneity (p = 0.2).
Discussion
Published data on epilepsy in LAC demonstrated a median
LTE prevalence of 15.8/1,000, a median AE prevalence of 10.7/
1,000 (both higher in rural areas), a median incidence of epilepsy
of 138.2/100,000 and an enormous TG in rural areas. Further-
more a median NCC proportion among PWE of 32.3% (by CT
scan) and a consistent association between NCC and epilepsy were
found.
To minimize biases we performed a comprehensive systematic
review, with particular attention to the main Latin American and
Caribbean biomedical databases. Nevertheless, lack of epidemio-
logical data on epilepsy from Nicaragua, Venezuela, Paraguay,
Suriname, Guyana and a high information gap on incidence,
mortality, TG and NCC prevalence in all LAC were pointed out,
confirming epilepsy and NCC as major neglected diseases in this
region.
The elevated burden of these diseases should be regarded as a
primary public-health issue in LAC, especially in rural settings.
Table 2. Neurocysticercosis prevalence among people with epilepsy in Latina American Countries.
RURAL URBAN
Country Diagnostic method
Number of
studies
Median
estimate
95% Confidence
Intervals
Number of
studies
Median
estimate
95% Confidence
Intervals
Brazil EITB assay / / / 2 11.4/100 5.5–19.1
CT scan / / / 6 28.2/100 16.9–41.0
Bolivia EITB assay 1 18.8/100 12.5–27.1 / / /
CT scan 1 21.0/100 14.2–29.8 / / /
Del Brutto 1 27.4/100 20.3–35.9 / / /
Colombia EITB assay / / / 1 9.8/100 /
CT scan / / / 1 13.9/100 11.3–17.1
Ecuador EITB assay 2 24.4/100 13.5–37.3 / / /
CT scan 2 40.9/100 17.9–66.3 / / /
Guatemala EITB assay 1 17.5/100 10.6–27.4 / / /
CT scan 1 47.4/100 36.5–58.4 / / /
Honduras EITB assay / / / / / /
CT scan 1 13.9/100 5.6–29.1 / / /
Del Brutto 1 36.7/100 27.4–47.0 / / /
Mexico EITB assay 2 24.9/100 17.4-33-3 / / /
CT scan 1 70.0/100 39.2–89.7 3 32.1/100 17.1–49.3
Nicaragua EITB assay / / / 1 14.8/100 8.7–23.8
CT scan / / / / / /
Panama EITB assay 1 0.0/100 / / / /
CT scan / / / / / /
Peru EITB assay 4 35.6/100 27.1–44.7 1 11.6/100 7.8–17.1
CT scan 3 40.5/100 28.3–53.3 1 54.1/100 38.4–69.0
EITB: enzyme-linked immunoelectrotransfer blot; CT scan: computed tomography scan.
doi:10.1371/journal.pntd.0002480.t002
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Although slightly lower, our estimates were close to those reported
in a previous meta-analysis (LTE prevalence 17.8/1,000; AE
prevalence 12.4/1,000, [7]) and above the median values reported
in a recent work considering both developed and developing
countries [3]. Also epilepsy incidence in urban and rural setting
was greater than that reported in another study analysing low- and
middle-income countries [6]. The pooled NCC proportion among
PWE was 32.3% (95% CI 26.0–39.0), higher than 29.0% (95% CI
22.9–35.5) reported in a meta-analysis including both rural and
urban areas worldwide [12]. NCC proportion found among PWE
in rural LAC (37.5%) appeared little lower than that reported in
studies applying same criteria in rural Africa (Burkina Faso 46.9%)
[46], rural India (40%) [47] and higher than that reported in rural
Tanzania (17.9%) [48]. Considering urban areas, our estimate
(29.4%) was similar to that reported in South Africa (28.0%) [49]
and in urban India (28.4%) [50].
For the first time, to the best of our knowledge, this study
demonstrated the influence of NCC prevalence on LTE and AE
prevalence in LAC: countries with a NCC proportion (EITB
assay) higher than 12.1%, among PWE living in urban areas, and
than 23.7%, among PWE living in rural areas, presented higher
LTE and AE estimates. We are aware that seropositivity at the
EITB reflects an exposure to the parasite not necessary
accompanied by a CNS involvement. However, this assay presents
a high sensitivity and specificity and, together with the presence of
compatible clinical manifestations (such as epilepsy) in people
living in endemic areas, allows to formulate the diagnosis of
probable NCC according the worldwide accepted diagnostic
Table 3. Meta-regression of lifetime epilepsy prevalence: Univariate and multivariable analysis.
UNIVARIATE MULTIVARIABLE
Odds ratio (95% CI) p- value Heterogeneity (t2)
Heterogeneity
(%) Odds ratio (95% CI) p- value
Study setting
Urban 1.0 / 1.0 /
Rural 1.6 (1.1–3.2) 0.05 0.48 29.2 1.3 (1.0–2.6) 0.07
Age group
All 1.0 / 1.0 /
Adults 2.3 (1.2–4.1) 0.03 0.44 12.9 1.6 (0.9–4.2) 0.5
Children 0.3 (0.2–1.9) 0.09 0.2 (0.1–1.2) 0.6
Epilepsy ascertainment
Q+E 1.0 / 1.0 /
Q+E+T 1.7 (0.6–7.2) 0.1 0.46 7.6 1.1 (0.5–6.3) 0.5
Type of estimate
Point 1.0 / / /
Period 0.2 (0.1–5.8) 0.8 0.52 23.7 / /
Study size
.20,000 1.0 / 1.0 /
1,000–20,000 1.9 (1.5–3.2) 0.001 0.34 32.7 1.4 (1.2–3.1) 0.04
,1,000 3.8 (2.8–9.3) 0.03 1.8 (1.5–8.2) 0.05
Definition of epilepsy
ILAE 1993 1.0 / / /
Other definition 0.5 (0.2–3.2) 0.6 0.51 22.7 / /
Questionnaire
WHO 1.0 / / /
Others 0.2 (0.1–2.4) 0.8 0.52 23.5 / /
Validated questionnaire
Yes 1.0 / / /
No 0.2 (0.1–9.5) 0.8 0.50 23.3 / /
Treatment gap
#50% 1.0 / 1.0 /
.50% 2.3 (1.3–7.4) 0.04 0.26 36.9 2.7 (2.1–6.9) 0.02
NCC prevalence
#median prevalence* 1.0 / 1.0 /
.median prevalence* 1.5 (0.9–5.8) 0.1 0.32 6.7 3.4 (1.3–5.2) 0.03
CC: cysticercosis; CI: confidence interval; E: neurological evaluation; NCC: neurocysticercosis Q: questionnaire; T: tool.
*median prevalence (EITB assay) estimates among people with epilepsy in Latin American countries: 12.1% for studies performed in urban areas, 23.7% for studies
performed in rural areas.
doi:10.1371/journal.pntd.0002480.t003
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criteria for NCC [17]. We could then state that NCC prevalence
seems to affect both LTE and AE prevalence, and that it could be
considered a source of variability of prevalence estimates across
LAC. The association between CC/NCC and epilepsy in LAC
was evaluated in nine studies using ‘‘prevalent’’ cases. There was a
consistent and significant association between epilepsy and CC/
NCC, with ORs of 2.7 for studies using EITB serology and 5.6 for
studies performing brain CT scan. Studies associating brain
imaging to serology are likely more accurate as include those cases
who present calcified or single parenchymal cyst which may be
asymptomatic or seronegative [51]. Previous meta-analysis data
from LAC did not exist, while in Africa a 3.4 to 3.8-fold increased
risk for developing epilepsy was reported [52].
The meta-regression analysis has also pointed out an influence
of TG on both AE and LTE estimates: since countries with higher
TG are those presenting a larger burden of untreated epilepsy, the
consequent increased number of active cases could lead to higher
AE prevalence. Moreover, as AE prevalence is included in LTE
measures (about the 38% for rural and 59% in urban population
of developing countries; [3]) the role of TG could also be reflected
on LTE estimates. On the other hand, in countries with lower TG,
‘‘not-active’’ cases are probably more frequent and more difficult
to detect in prevalence surveys, leading to an underestimation of
the LTE prevalence.
When considered together, TG and NCC prevalence together
explained a very great amount of AE prevalence variability (up to
Table 4. Meta-regression of active epilepsy prevalence: Univariate and multivariable analysis.
UNIVARIATE MULTIVARIABLE
Odds ratio (95% CI) p- value Heterogeneity (t2)
Heterogeneity
(%) Odds ratio (95% CI) p- value
Study setting
Urban 1.0 / 1.0 /
Rural 1.4 (1.1–3.4) 0.05 0.30 20.7 1.4 (0.9–3.0) 0.08
Age group
All 1.0 / / /
Adults 1.1 (0.7–2.4) 0.9 0.33 29.7 / /
Children 1.3 (0.3–1.2) 0.8 / /
Epilepsy ascertainment
Q+E 1.0 / 1.0 /
Q+E+T 2.0 (1.3–5.7) 0.05 0.21 41.8 1.8 (0.8–5.2) 0.09
Type of estimate
Point 1.0 / / /
Period 0.2 (0.1–2.3) 0.8 0.32 28.1 / /
Study size
.20,000 1.0 / 1.0 /
1,000–20,000 1.2 (1.1–2.0) 0.05 0.30 10.7 1.5 (0.8–2.1) 0.1
,1,000 1.6 (0.9–5.3) 0.06 1.7 (0.7–4.2) 0.1
Definition of epilepsy
ILAE 1993 1.0 / 1.0 /
Other definition 0.5 (0.4–1.1) 0.2 0.26 11.3 0.8 (0.2–0.9) 0.04
Questionnaire
WHO 1.0 / / /
Others 0.5 (0.2–2.5) 0.6 0.33 210.7 / /
Validated questionnaire
Yes 1.0 / / /
No 1.1 (0.8–7.3) 0.3 0.29 1.4 / /
Treatment gap
#50% 1.0 / 1.0 /
.50% 1.7 (1.2–4.5) 0.05 0.11 41.6 1.6 (0.8–4.2) 0.09
NCC prevalence
#median prevalence* 1.0 / 1.0 /
.median prevalence* 2.1 (1.9–6.3) 0.05 0.10 12.5 2.7 (2.3–5.6) 0.05
CC: cysticercosis; CI: confidence interval; E: neurological evaluation; NCC: neurocysticercosis Q: questionnaire; T: tool.
*median seroprevalence (EITB) estimates among people with epilepsy in Latin American countries: 12.1% for studies performed in urban areas, 23.7% for studies
performed in rural areas.
doi:10.1371/journal.pntd.0002480.t004
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85.4%) suggesting that interventions on these modifiable factors
could result in important reduction of AE burden.
Finally, our data showed a non significant increase in mortality
in PWE in LAC (SMR 1.4; 95% CI 0.01–6.1). Studies in
developed countries have reported mortality rates two to three
times higher in PWE than in the general population [53]. This
increase includes direct and indirect consequences of epilepsy, as
well as underlying disorders responsible for secondary epilepsies
[54].We found only five eligible papers reporting SMR in LAC
(Argentina, Bolivia, Brazil, Chile and Ecuador) ranging from 0.76
in Brazil [44] to 6.3 in Ecuador [55]. These studies presented a
prevalent cohort designs that might have underestimate short-term
mortality, as patients with more serious disease die earlier and are
not included in the observation period. Furthermore, SMR is
highest in symptomatic epilepsy (ranging from 2.2–6.5, [53]) while,
in idiopathic epilepsy, conflicting results have been reported, often
showing a non significant increase, as the one found here. Only in
the Bolivian study [56], SMR was estimated stratifying by
symptomatic and idiopathic epilepsy, with increased mortality
reported only among patients with symptomatic epilepsy
(SMR = 3.0; 95% CI 1.2–6.3).
Concluding, this systematic review demonstrated a high burden
of epilepsy and of NCC in LAC with marked detriment of rural
areas, identified two important modifiable factors related to
epilepsy prevalence and a consistent association between NCC
and epilepsy in LAC. We are aware about the possible loss of
power related to the dichotomization of continuous variables in
the meta-regression. However, the paucity of studies found on
NCC and on TG in particular, made our analysis not able to
support a larger number of categories. Moreover, the reported
narrow CIs suggest that the loss of statistical power was minimal.
Additional data are needed to better understand the possible
sources of heterogeneity among countries and determine the
situation in those regions that are still under the shadows.
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